FILING ANALYSIS · FRIDAY, NOVEMBER 6
bioAffinity Technologies, Inc. BIAF — 8-K: Results of Operations and Financial Condition
neutral
The company reported a 79% increase in CyPath Lung testing revenue and a 100% increase in test unit sales, but also raised $8.0 million in gross proceeds through private and registered direct offerings, which may lead to dilution
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →